GlobeNewswire Inc.··Okyo Pharma LimitedOKYO Pharma to Showcase Urcosimod Data at ASCRS Meeting Ahead of Late-Stage Trial
OKYO Pharma presents Phase 2 urcosimod data at ASCRS conference; plans Phase 2b/3 trial launch in H1 2026 for neuropathic corneal pain.
OKYOPhase 2 clinical trialbiopharmaceutical